LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Inicio・Lista de Acciones・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Cerrado

SectorSanidad

12.1 -3.35

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

11.94

Máximo

12.54

Métricas clave
By Trading Economics
Ingresos	6.8M -12M
Ventas	3.5M 19M
Margen de beneficios	-64.131
Empleados	120
EBITDA	7.4M -7.6M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+57.23% upside

Dividendos
By Dow Jones
Próximas Ganancias	11 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-34M 367M
Apertura anterior	15.45
Cierre anterior	12.1

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

82 / 349 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

5.04 / 5.44 Soporte y Resistencia

ENANTA PHARMACEUTICALS INC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 mar 2026, 17:33 UTC

Noticias de Eventos Importantes

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mar 2026, 17:00 UTC

Noticias de Eventos Importantes

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mar 2026, 16:03 UTC

Noticias de Eventos Importantes

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 mar 2026, 14:50 UTC

Principales Movimientos del Mercado

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 mar 2026, 14:37 UTC

Adquisiciones, fusiones, absorciones

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 mar 2026, 14:29 UTC

Noticias de Eventos Importantes

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27 mar 2026, 14:16 UTC

Noticias de Eventos Importantes

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

27 mar 2026, 19:16 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mar 2026, 19:07 UTC

Charlas de Mercado

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mar 2026, 19:04 UTC

Charlas de Mercado

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mar 2026, 19:03 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 19:02 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mar 2026, 18:12 UTC

Charlas de Mercado

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mar 2026, 17:36 UTC

Noticias de Eventos Importantes

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mar 2026, 17:34 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mar 2026, 17:29 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mar 2026, 16:38 UTC

Charlas de Mercado

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mar 2026, 16:32 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mar 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

27 mar 2026, 15:43 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mar 2026, 15:25 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 15:25 UTC

Charlas de Mercado

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 mar 2026, 15:00 UTC

Noticias de Eventos Importantes

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 mar 2026, 15:00 UTC

Noticias de Eventos Importantes

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 mar 2026, 15:00 UTC

Noticias de Eventos Importantes

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 mar 2026, 14:36 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 mar 2026, 14:26 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27 mar 2026, 14:14 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 14:14 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

Comparación entre iguales

Cambio de precio

ENANTA PHARMACEUTICALS INC previsión

Precio Objetivo

By TipRanks

57.23% repunte

Estimación a 12 Meses

Media 19.67 USD 57.23%

Máximo 20 USD

Mínimo 19 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ENANTA PHARMACEUTICALS INC Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para ENANTA PHARMACEUTICALS INC Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.04 / 5.44Soporte y Resistencia

Recent bearish events outweigh bullish events.

There are no events.

Sentimiento

By Acuity

82 / 349 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.